Archive for the 'Asia News' Category

The Truth Behind China Bribery Scandals

VLUU L110  / Samsung L110The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China. Big names were engulfed in the scandal, including GSK, AstraZeneca, Sanofi, Novartis, Eli Lilly, Novo Nordisk and UCB amongst others.

Last month, four GSK executives were put under investigation for allegedly paying up to $480 million to doctors, hospital administrators, government officials and medical groups to promote the use of its medications. The limelight then shifted to Sanofi when some of its employees were accused of paying bribes totaling up to $280,000 to more than 500 Chinese doctors across 79 hospitals six years ago. The newspapers also alleged that Sanofi paid doctors 80 yuan each time a patient bought its products, with the largest payment said to be 11,200 yuan.

Novartis has also fallen prey to bribery allegations in China. The Swiss drug maker was accused of paying doctors $8000 to prescribe its cancer drug, Sandostatin LAR. Sales figures were expected to increase in June and July this year as a result. Eli Lilly is now the latest being investigated after a former employee alleged in a report that the company spent more than $490,000 to bribe doctors in China. The former sales manager said that Eli Lilly offered kickbacks to ensure doctors used its drugs, including its insulin brand. Read more »

Pharma 2012 Layoffs

Borders on Intellectual Property

An upcoming report on India’s pharmaceutical industry in PharmTech (check out the October 2012 issue) discusses India’s strict patent policies and got me thinking about the rights of intellectual property versus patients’ rights to needed medicines. PharmTech’s Asia correspondent, Jane Wan, reports that India has set a high bar for patent approval that Western drug manufacturers are finding frustrating.

Read more »

BRIC Retains Pharma Investments

Stephanie Sutton Pharm Tech EuropeEmerging markets continue to attract the attention of pharmaceutical companies thanks to their high growth and large patient populations. Back in 2011, the locations of focus were the so-called ‘BRIC’ countries (Brazil, Russia, India and China). But with more markets emerging and drawing the eyes of the pharmaceutical industry have the original BRIC countries lost some of pharma’s favour?

Not at all, judging by several developments this year. Read more »

Increased Generics Spending in Pharmerging Markets Predicted

The pharmerging nations are expected to nearly double their spending on medicine by 2016, according to an IMS Institute for Healthcare Informatics report, The Global Use of Medicines: Outlook through 2016, the Institute said in a press release. Read more »

India Changes Foreign Direct Investment Plans

Written by A. Nair, a PharmTech correspondent based in Mumbai

After months of deliberation, the Indian government has decided not to cap foreign direct investment (FDI) in the pharmaceutical sector and to continue with the 100% FDI regime. A decision in this regard was taken by an inter ministerial group presided over by India’s Prime Minister Manmohan Singh, which sought to allay fears about clearing investments automatically. Read more »

Pharma Free Trade Winds A Blowing

Patricia Van Arnum PharmTech editor Free trade, always a subject of concern for business, has been a topic of particular interest for the pharmaceutical and allied industries this past week as individual companies and trade associations weigh in on the debate on several free-trade measures. Read more »

Partnering with India

Partnerships between US and Asian companies have become a prominent feature of pharmaceutical development and manufacturing.  To foster relationships between US and Indian biopharmaceutical companies, the US–India BioPharma and Healthcare Summit was held in Cambridge, MA on June 23, 2011. The summit is an annual event, bringing together representatives from large US/European pharmaceutical companies, smaller US companies, academia, and patient interest groups with representatives of the Indian government and industry to discuss issues surrounding US–Indian partnering in biopharmaceutical development. Read more »

Lower Vaccine Prices For Developing Countries

Stephanie Sutton Pharm Tech EuropeThis week has seen several pharma companies slashing the prices of important vaccines for use in developing countries, but is the move spurred by simple generosity alone? There are often headlines about pharma companies’ drug donations to developing countries and I think it’s great to see the pharma industry making a difference in this area. However, the price reductions may also stem from something other than generosity: the need to compete with other vaccine manufacturers, particularly at a time where more and more low-cost generic medicines are becoming available. Read more »

Pharma Supports Earthquake Efforts In Japan

Stephanie Sutton Pharm Tech EuropeSince last Friday, I’m sure almost all of us have been watching as Japan deals with the horrific aftermath of the earthquake and tsunami. I was fortunate enough to be in Japan this time last year. I think it’s a wonderful country and it’s heartbreaking to see what’s happening to the Japanese people now. Given the devastation to human lives — 6539 confirmed dead and more than 87000 buildings damaged, according to Reuters — the financial implications seem much less dire to me. However, this is the pharm tech blog so I think it’s a good idea to leave the human losses to other media sources and to concentrate on the effects the disaster has had on the pharmaceutical industry. Read more »

Next Page »